Skip to content
AnalystLens

Merck Annual Report, Year Ended Dec 31, 2013

Filing Date
Filed February 27, 2014
Period End
December 31, 2013
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Restructuring8-K · Jul ’25Jul ’25

Summary

Summary of the 10-K filed February 27, 2014. Cited figures are marked; the original filing is the authoritative source.

Merck & Co., Inc. reported total sales of $44.03 billiona for the fiscal year ended December 30, 2013.

This represents a 7% decrease from the previous year, largely attributed to the loss of market exclusivity for key products like Singulair, coupled with ongoing global healthcare cost containment pressures. Despite the revenue decline, Merck demonstrated effective cost management, with marketing and administrative expenses and R&D costs decreasing by over $1.5 billionb combined compared to 2012.

The company also highlighted a significant restructuring program initiated in October 2013, aiming to reduce its workforce by approximately 8,500 positions and sharpen its commercial and R&D focus to drive future growth. Merck continued to return value to shareholders, repurchasing shares and paying dividends, signaling confidence in its long-term strategy and pipeline.

Key Highlights

  1. Total sales for 2013 were $44.03 billion, a 7% decrease from $47.27 billion in 2012, primarily due to patent expiries of major products like Singulair.
  2. Significant cost-saving measures were implemented, with combined Marketing & Administrative and R&D expenses decreasing by over $1.5 billion compared to 2012.
  3. Merck announced a major global restructuring program targeting approximately 8,500 job reductions to streamline operations and focus on key therapeutic areas: diabetes, acute hospital care, vaccines, and oncology.
  4. The company continued to prioritize shareholder returns, repurchasing $6.5 billion of its common stock and raising its quarterly dividend.
  5. Key products showing growth included Gardasil (vaccine), Remicade and Simponi (immunology), Janumet (diabetes), and Isentress (HIV).
  6. Merck is actively managing its product pipeline, with several candidates under regulatory review, including the nine-valent HPV vaccine (V503) and an anti-PD-1 immunotherapy (MK-3475) for advanced melanoma.
  7. The company is evaluating strategic options for its Animal Health and Consumer Care businesses to enhance long-term value creation.

Financial Statements

FY2013 against FY2012

Line itemFY2013FY2012Change
Revenue$44.03B$47.27B−6.8%
Cost of Revenue$16.95B$16.45B+3.1%
Gross Profit$27.08B$30.82B−12.1%
R&D Expenses$7.50B$8.17B−8.1%
SG&A Expenses$11.91B$12.78B−6.8%
Interest Expense$801.00M$714.00M+12.2%
Net Income$4.40B$6.17B−28.6%
EPS (Basic)$1.49$2.03−26.6%
EPS (Diluted)$1.47$2.00−26.5%
Shares Outstanding (Basic)2.96B3.04B−2.6%
Shares Outstanding (Diluted)3.00B3.08B−2.6%

Frequently Asked Questions

  1. What was Merck's financial performance in 2013?

    Merck reported total sales of $44.03 billion in 2013, a decrease of 7% from 2012. This decline was primarily driven by the loss of market exclusivity for key products such as Singulair and ongoing global healthcare cost containment pressures. Net income attributable to Merck & Co., Inc. was $4.4 billion in 2013, compared to $6.2 billion in 2012.

  2. What significant strategic initiatives did Merck undertake in 2013?

    Merck announced a major global restructuring program in October 2013, aiming to reduce its workforce by approximately 8,500 positions to sharpen its commercial and R&D focus. The company also initiated a review of its Animal Health and Consumer Care businesses to explore strategic options for long-term value creation.

  3. Which product categories or specific products showed strong performance in 2013?

    Despite overall sales decline, Merck saw growth in several areas. Vaccines, particularly Gardasil, showed strong performance. In therapeutic areas, immunology products like Remicade and Simponi, diabetes treatments Janumet, and the HIV medication Isentress also contributed positively to sales.

  4. What are the key risks and challenges facing Merck as highlighted in the filing?

    Key risks and challenges include significant competition from generic products following patent expiries, increasing pricing pressures globally from healthcare cost containment efforts, potential delays or failures in new product development and regulatory approvals, and ongoing litigation, notably related to Vioxx and Fosamax.